Diabetic Macular Edema - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Diabetic Macular Edema Pipeline Review, Q4 2010”, provides an overview of the Diabetic Macular Edema therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema . “Diabetic Macular Edema -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Markets Direct’s, “Diabetic Macular Edema Pipeline Review, Q4 2010”, provides an overview of the Diabetic Macular Edema therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema . “Diabetic Macular Edema -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Diabetic Macular Edema .
- A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Macular Edema pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- A snapshot of the global therapeutic scenario for Diabetic Macular Edema .
- A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Macular Edema pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Diabetic Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Macular Edema
Diabetic Macular Edema Therapeutics under Development by Companies
Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Diabetic Macular Edema Therapeutics Development
Allergan, Inc.
Eli Lilly and Company
Nektar Therapeutics
Isis Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Novagali Pharma SA
Novartis AG
Pfizer Inc.
OPKO Health, Inc.
NicOx SA
SANWA KAGAKU KENKYUSHO CO.,LTD.
Regeneron Pharmaceuticals, Inc.
Sareum Holdings plc
CoMentis, Inc.
Molecular Partners AG
Alimera Sciences, Inc.
Charlesson LLC.
Aleris AB
NicOx Inc.
Ampio Pharmaceuticals, Inc.
Universities/Institutes Involved in Diabetic Macular Edema Therapeutics Development
Diabetic Macular Edema Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Arxxant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iluvien - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ozurdex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone + Nevanac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Diabetic Macular Edema - Featured News
Oct 22, 2010: Novartis therapy Lucentis Recommended For Approval In EU To Treat Patients With Vision Loss Due To Diabetic Macular Edema
Oct 12, 2010: Alimera Sciences' FAME Study Data On Iluvien To Be Presented At AAO Annual Meeting
Aug 31, 2010: pSivida Receives FDA Priority Review For Iluvien For Treatment Of Diabetic Macular Edema
Aug 30, 2010: Alimera Receives FDA Priority Review For Iluvien For Treatment Of Diabetic Macular Edema
Jul 26, 2010: iCo Therapeutics Receives Health Canada Clearance To Conduct Phase II DME Trial With iCo-007
Jul 22, 2010: Ampio Initiates Phase II Clinical Trial Of Optina For Treatment Of Diabetic Macular Edema
Jul 08, 2010: Alimera Submits Iluvien MAA For Treatment Of Diabetic Macular Edema
Jun 29, 2010: pSivida Submits NDA To FDA For Iluvien To Treat Diabetic Macular Edema
Jun 29, 2010: InteKrin Presents Phase IIb Clinical Data Of INT131 For Treatment Of Diabetic Edema At American Diabetes Association Annual Meeting
Jun 28, 2010: NicOx Presents Preclinical Data Of NCX 434 At Retina International World Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Diabetic Macular Edema, 2010
Products under Development for Diabetic Macular Edema – Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2010
Allergan, Inc., 2010
Eli Lilly and Company, 2010
Nektar Therapeutics, 2010
Isis Pharmaceuticals, Inc., 2010
Santen Pharmaceutical Co., Ltd., 2010
Novagali Pharma SA, 2010
Novartis AG, 2010
Pfizer Inc., 2010
OPKO Health, Inc., 2010
NicOx SA, 2010
SANWA KAGAKU KENKYUSHO CO.,LTD., 2010
Regeneron Pharmaceuticals, Inc., 2010
Sareum Holdings plc, 2010
CoMentis, Inc., 2010
Molecular Partners AG, 2010
Alimera Sciences, Inc., 2010
Charlesson LLC., 2010
Aleris AB, 2010
NicOx Inc., 2010
Ampio Pharmaceuticals, Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 56
LIST OF FIGURES
Number of Products under Development for Diabetic Macular Edema, 2010
Products under Development for Diabetic Macular Edema – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Discovery and Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 38
Global Markets Direct Report Coverage
Diabetic Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Macular Edema
Diabetic Macular Edema Therapeutics under Development by Companies
Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Diabetic Macular Edema Therapeutics Development
Allergan, Inc.
Eli Lilly and Company
Nektar Therapeutics
Isis Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Novagali Pharma SA
Novartis AG
Pfizer Inc.
OPKO Health, Inc.
NicOx SA
SANWA KAGAKU KENKYUSHO CO.,LTD.
Regeneron Pharmaceuticals, Inc.
Sareum Holdings plc
CoMentis, Inc.
Molecular Partners AG
Alimera Sciences, Inc.
Charlesson LLC.
Aleris AB
NicOx Inc.
Ampio Pharmaceuticals, Inc.
Universities/Institutes Involved in Diabetic Macular Edema Therapeutics Development
Diabetic Macular Edema Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Arxxant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iluvien - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ozurdex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lucentis + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone + Laser Photocoagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone + Nevanac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Diabetic Macular Edema - Featured News
Oct 22, 2010: Novartis therapy Lucentis Recommended For Approval In EU To Treat Patients With Vision Loss Due To Diabetic Macular Edema
Oct 12, 2010: Alimera Sciences' FAME Study Data On Iluvien To Be Presented At AAO Annual Meeting
Aug 31, 2010: pSivida Receives FDA Priority Review For Iluvien For Treatment Of Diabetic Macular Edema
Aug 30, 2010: Alimera Receives FDA Priority Review For Iluvien For Treatment Of Diabetic Macular Edema
Jul 26, 2010: iCo Therapeutics Receives Health Canada Clearance To Conduct Phase II DME Trial With iCo-007
Jul 22, 2010: Ampio Initiates Phase II Clinical Trial Of Optina For Treatment Of Diabetic Macular Edema
Jul 08, 2010: Alimera Submits Iluvien MAA For Treatment Of Diabetic Macular Edema
Jun 29, 2010: pSivida Submits NDA To FDA For Iluvien To Treat Diabetic Macular Edema
Jun 29, 2010: InteKrin Presents Phase IIb Clinical Data Of INT131 For Treatment Of Diabetic Edema At American Diabetes Association Annual Meeting
Jun 28, 2010: NicOx Presents Preclinical Data Of NCX 434 At Retina International World Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Diabetic Macular Edema, 2010
Products under Development for Diabetic Macular Edema – Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2010
Allergan, Inc., 2010
Eli Lilly and Company, 2010
Nektar Therapeutics, 2010
Isis Pharmaceuticals, Inc., 2010
Santen Pharmaceutical Co., Ltd., 2010
Novagali Pharma SA, 2010
Novartis AG, 2010
Pfizer Inc., 2010
OPKO Health, Inc., 2010
NicOx SA, 2010
SANWA KAGAKU KENKYUSHO CO.,LTD., 2010
Regeneron Pharmaceuticals, Inc., 2010
Sareum Holdings plc, 2010
CoMentis, Inc., 2010
Molecular Partners AG, 2010
Alimera Sciences, Inc., 2010
Charlesson LLC., 2010
Aleris AB, 2010
NicOx Inc., 2010
Ampio Pharmaceuticals, Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 56
LIST OF FIGURES
Number of Products under Development for Diabetic Macular Edema, 2010
Products under Development for Diabetic Macular Edema – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Discovery and Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 38